TY - JOUR
T1 - Effects of Cancer Presence and Therapy on the Platelet Proteome
AU - Walraven, Maudy
AU - Sabrkhany, Siamack
AU - Knol, Jaco C
AU - Dekker, Henk
AU - de Reus, Inge
AU - Piersma, Sander R
AU - Pham, Thang V
AU - Griffioen, Arjan W
AU - Broxterman, Henk J
AU - Oude Egbrink, Mirjam
AU - Verheul, Henk M W
AU - Jimenez, Connie R
PY - 2021/8/1
Y1 - 2021/8/1
N2 - Platelets are involved in tumor angiogenesis and cancer progression. Previous studies indicated that cancer could affect platelet content. In the current study, we investigated whether cancer-associated proteins can be discerned in the platelets of cancer patients, and whether antitumor treatment may affect the platelet proteome. Platelets were isolated from nine patients with different cancer types and ten healthy volunteers. From three patients, platelets were isolated before and after the start of antitumor treatment. Mass spectrometry-based proteomics of gel-fractionated platelet proteins were used to compare patients versus controls and before and after treatment initiation. A total of 4059 proteins were detected, of which 50 were significantly more abundant in patients, and 36 more in healthy volunteers. Eight of these proteins overlapped with our previous cancer platelet proteomics study. From these data, we selected potential biomarkers of cancer including six upregulated proteins (RNF213, CTSG, PGLYRP1, RPL8, S100A8, S100A9) and two downregulated proteins (GPX1, TNS1). Antitumor treatment resulted in increased levels of 432 proteins and decreased levels of 189 proteins. In conclusion, the platelet proteome may be affected in cancer patients and platelets are a potential source of cancer biomarkers. In addition, we found in a small group of patients that anticancer treatment significantly changes the platelet proteome.
AB - Platelets are involved in tumor angiogenesis and cancer progression. Previous studies indicated that cancer could affect platelet content. In the current study, we investigated whether cancer-associated proteins can be discerned in the platelets of cancer patients, and whether antitumor treatment may affect the platelet proteome. Platelets were isolated from nine patients with different cancer types and ten healthy volunteers. From three patients, platelets were isolated before and after the start of antitumor treatment. Mass spectrometry-based proteomics of gel-fractionated platelet proteins were used to compare patients versus controls and before and after treatment initiation. A total of 4059 proteins were detected, of which 50 were significantly more abundant in patients, and 36 more in healthy volunteers. Eight of these proteins overlapped with our previous cancer platelet proteomics study. From these data, we selected potential biomarkers of cancer including six upregulated proteins (RNF213, CTSG, PGLYRP1, RPL8, S100A8, S100A9) and two downregulated proteins (GPX1, TNS1). Antitumor treatment resulted in increased levels of 432 proteins and decreased levels of 189 proteins. In conclusion, the platelet proteome may be affected in cancer patients and platelets are a potential source of cancer biomarkers. In addition, we found in a small group of patients that anticancer treatment significantly changes the platelet proteome.
KW - Aged
KW - Antineoplastic Agents/therapeutic use
KW - Biomarkers, Tumor/blood
KW - Blood Platelets/metabolism
KW - Digestive System Neoplasms/blood
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Proteome/genetics
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85111361244&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/34361002
U2 - https://doi.org/10.3390/ijms22158236
DO - https://doi.org/10.3390/ijms22158236
M3 - Article
C2 - 34361002
SN - 1422-0067
VL - 22
JO - International journal of molecular sciences
JF - International journal of molecular sciences
IS - 15
M1 - 8236
ER -